Literature DB >> 8811169

New insights into the genetics of Alzheimer's disease.

J Hardy1.   

Abstract

In early 1993, the genetic data implicating the amyloid precursor protein as one of the loci leading to early onset Alzheimer's disease were reviewed (Hardy and Duff, Annals of Medicine, 25: 437-440), together with the evidence implicating abnormal deposition of beta-amyloid as the initiating point of the process leading to the disease. Since that time, three other genetic loci have been directly implicated in the aetiology of the disease: the apolipoprotein E locus on chromosome 19, the presenilin 1 gene on chromosome 14 and the presenilin 2 gene on chromosome 1. In this article, I review the progress over the last three years and attempt to assess whether the evidence for the amyloid cascade hypothesis still stands scrutiny.

Entities:  

Mesh:

Year:  1996        PMID: 8811169     DOI: 10.3109/07853899609033127

Source DB:  PubMed          Journal:  Ann Med        ISSN: 0785-3890            Impact factor:   4.709


  15 in total

Review 1.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

2.  Intradermal active full-length DNA Aβ42 immunization via electroporation leads to high anti-Aβ antibody levels in wild-type mice.

Authors:  Roger N Rosenberg; Min Fu; Doris Lambracht-Washington
Journal:  J Neuroimmunol       Date:  2018-06-11       Impact factor: 3.478

Review 3.  Potential treatment opportunities for Alzheimer's disease through inhibition of secretases and Abeta immunization.

Authors:  D Schenk; D Games; P Seubert
Journal:  J Mol Neurosci       Date:  2001-10       Impact factor: 3.444

Review 4.  Amyloid beta-protein assembly and Alzheimer disease.

Authors:  Robin Roychaudhuri; Mingfeng Yang; Minako M Hoshi; David B Teplow
Journal:  J Biol Chem       Date:  2008-10-09       Impact factor: 5.157

5.  DNA beta-amyloid(1-42) trimer immunization for Alzheimer disease in a wild-type mouse model.

Authors:  Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal:  JAMA       Date:  2009-10-28       Impact factor: 56.272

6.  DNA immunization against amyloid beta 42 has high potential as safe therapy for Alzheimer's disease as it diminishes antigen-specific Th1 and Th17 cell proliferation.

Authors:  Doris Lambracht-Washington; Bao-Xi Qu; Min Fu; Larry D Anderson; Olaf Stüve; Todd N Eagar; Roger N Rosenberg
Journal:  Cell Mol Neurobiol       Date:  2011-04-06       Impact factor: 5.046

Review 7.  Changes in the ageing brain in health and disease.

Authors:  B H Anderton
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-12-29       Impact factor: 6.237

8.  Clinical rationale of genetic testing in dementia.

Authors:  G B Frisoni; M Trabucchi
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-03       Impact factor: 10.154

9.  Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.

Authors:  J J Lucas; F Hernández; P Gómez-Ramos; M A Morán; R Hen; J Avila
Journal:  EMBO J       Date:  2001-01-15       Impact factor: 11.598

10.  A peptide prime-DNA boost immunization protocol provides significant benefits as a new generation Aβ42 DNA vaccine for Alzheimer disease.

Authors:  Doris Lambracht-Washington; Bao-xi Qu; Min Fu; Larry D Anderson; Todd N Eagar; Olaf Stüve; Roger N Rosenberg
Journal:  J Neuroimmunol       Date:  2012-10-01       Impact factor: 3.478

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.